Market Exclusive

Analyst Upgrades – Cipher Pharmaceuticals (TSE:CPH) Stock Gets Upgraded By Bloom Burton from Hold to Buy

Analyst Ratings For Cipher Pharmaceuticals (TSE:CPH)

Today, Cipher Pharmaceuticals (TSE:CPH) stock received an upgrade by Bloom Burton from Hold to Buy.

There are 2 hold ratings, 1 buy rating on the stock.

The current consensus rating on Cipher Pharmaceuticals (TSE:CPH) is Hold (Score: 2.33) with a consensus target price of C$6.38 per share, a potential .

Some recent analyst ratings include


About Cipher Pharmaceuticals (TSE:CPH)
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Recent Trading Activity for Cipher Pharmaceuticals (TSE:CPH)
Shares of Cipher Pharmaceuticals closed the previous trading session at 5.06 up +0.06 1.20% with 32,258 shares trading hands.

Exit mobile version